The molecular basis and treatment of primary immunodeficiency disorders

Current Opinion in Pediatrics

Volumn 9, Issue 6, 1997, Pages 570-576

  Smart, Brian A ^a   Ochs, Hans D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAMMAGLOBULINEMIA; AUTOSOMAL INHERITANCE; COMBINED IMMUNODEFICIENCY; GENE THERAPY; HUMAN; IMMUNE DEFICIENCY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKAGE;

EID: 0031434764     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199712000-00004     Document Type: Review

References (69)

1. Stephan JL, Vlekova V, Le Deist F, Blanche S, Donadieu J, De Saint Basile G, Durandy A, Griscelli C, Fischer A: Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 1993, 123:564-572.
2. Rosen FS, Cooper MD, Wedgwood RJP: The primary immunodeficiencies. N Engl J Med 1995, 333:431-440.
3. Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, Roberts JL, Puck JM: Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight Infants. J Pediatr 1997, 130:378-387. This is a report of the clinical and laboratory presentation of a large series of patients with SCID which is useful because it compares and differentiates different forms of SCID.
4. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ: Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73:147-157.
5. Puck JM, Deschenes SM, Porter JC, Dutra AS, Brown CJ, Willard HF, Henthom PS: The interleukin-2 receptor γ chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficency, SCIDX1. Hum Mol Genet 1993, 2:1099-1104.
6. Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K, Sugamura K: Sharing of the interleukin-2 (IL2) receptor γ chain between receptors for IL-2 and IL-4. Science 1993, 262:1874-1877.
7. Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X, Leonard WJ: Interleukin-2 receptor γ chain: a functional component of the interleukin-7 receptor. Science 1993, 262:1877-1880.
8. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D, Anderson D: Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994, 13:2822-2830.
9. Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Nakamura M, Takeshita T: The common γ chain for multiple cytokine receptors. Adv Immunol 1995, 59:225-277.
10. Disanto JP, Keever CA, Small TN, Nichols GL, O'Reilly RJ, Flomenberg N: Absence of interleukin 2 production in a severe combined immunodeficiency disease syndrome with T cells. J Exp Med 1990, 171:1697-1704.
11. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I: Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991, 352:621-624.
12. von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SEG, Murray R: Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995, 181:1519-1526.
13. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, et al.: Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994, 180:1955-1960.
14. Maki K, Sunaga S, Komagata Y, Kodaira Y, Mabuchi A, Karasuyama H, Yokomuro K, Miyazaki J, Ikuta K: Interleukin 7 receptor-deficient mice lack γδ T cells. Proc Natl Acad Sci U S A 1996, 93:7172-7177.
15. c chain in a severe combined immune deficiency X1 patient. Blood 1996, 88:1707-1717.
16. Macchi P, Villa A, Gilliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ, et al.: Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65-68.
17. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone T, Noguchi M, Markert ML, Buckley RH, et al.: Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development Science 1995, 270:797-800.
18. Nosaka T, van Deursen JMA, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN: Defective lymphoid development in mice lacking Jak3. Science 1995, 270:800-802.
19. Taniguchi T: Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995, 268:251-255.
20. Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, Friedrich W, Seger RA, Hansen-Hagge TE, Desiderio S, et al.: RAG mutations in human B cell-negative SCID. Science 1996, 274:97-99. This is the first report of mutations of the recombinase activating genes (RAG). A remarkable proportion of B-cell negative patients with SCID studied (six of 14) were found to have RAG mutations, indicating that this may be an relatively common cause of SCID.
21. Shyur S, Hill HR: Recent advances in the genetics of primary immunodeficiency syndromes. J Pediatr 1996, 129:8-24. This is a good and fairly comprehensive review of the genetics of the primary immunodeficiency syndromes.
22. Ochs HD, Smith CIE: X-linked agammaglobulinemia: a clinical and molecular analysis. Medicine (Baltimore) 1996, 75:287-299.
23. Ochs HD: The molecular basis of primary immunodeficiency disorders. In Intravenous Immunoglobulin Research and Therapy. Edited by Kazatckine MD, Morell A. London:The Parthenon Publishing Group; 1996:175-191. This is a review of the primary immunodeficiency disorders with special, detailed attention to XLA, X-linked hyper-IgM syndrome, Wiskott-Aldrich syndrome, ataxia-telangiectasia, and the various forms of SCID.
24. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohanadas T, Quan, S, et al.: Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993, 72:279-290.
25. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bobrow M, et al.: The gene involved in X-linked agammaglobulinemia is a member of the src family of proteln-tyrosine kinases. Nature 1993, 361:226-233.
26. Fukuda M, Kojima T, Kabayama H, Mikoshiba K: Mutation of the p-strin homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity. J Biol Chem 1996, 271:30303-30306.
27. Takata M, Kurosaki T: A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-72. J Exp Med 1996, 184:31-40.
28. Anderson JS, Teutsch M, Dong Z, Wortis HH: An essential rote for tyrosine kinase in the regulation of Bruton's B-cell apoptosis. Proc Natl Acad Sci U S A 1996, 93:10966-10971.
29. de Weers M, Brouns GS, Hinshelwood S, Kinnon C, Schuurman RKB, Hendnks RW, Borst J: B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem 1994, 269:23857-23860.
30. Aoki Y, Isselbacher KJ, Pillai S: Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci U S A 1994, 91:10606-10609.
31. Yel L, Minegishi Y, Coustan-Smith E, Buckley RH, Trubel H, Pachman LM, Kitchingman GR, Campana D, Rohrer J, Conley ME: Mutatins in the μ heavy-chain gene in patients with agammaglobulinemia. N Engl J Med 1996, 335:1486-1493. This is the first molecular description of patients with agammaglobulinemia of autosomal inheritance. This report also serves to illustrate the importance of an intact, membrane-bound μ chain to B-cell development.
32. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA: A multi-institutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994, 125:876-885.
33. Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ: The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood 1980, 55:243-252.
34. Derry JMJ, Ochs HD, Francke U: Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994, 78:635-44.
35. Kenney D, Cairns L, Remold-O'Donnell E, Peterson J, Rosen FS, Parkman R: Morphological abnormalities in the lymphocytes of patients with the Wiskott-Aldrich syndrome. Blood 1986, 68:1329-1332.
36. Remold-O'Donnell E, Rosen FS, Kenney DM: Defects in Wiskott-Aldrich syndrome blood cells. Blood 1996, 87:2621-2631.
37. Rivero-Lezcano OM, Marcilla A, Sameshima JH, Robbins KC: Wiskott-Aldrich syndrome protein physically associates with Nck through Src homology 3 domains. Mol Cell Biol 1995, 15:5725-5731.
38. Finan PM, Soames CJ, Wilson L, Nelson DL, Stewart DM, Truong O, Hsuan JJ, Kellie S: Identification of regions of the Wiskott-Aldrich syndrome protein responsible for association with selected Src homology 3 domains. J Biol Chem 1996, 271:26291-26295.
39. Banin S, Truong O, Katz DR, Waterfield MD, Brickell PM, Gout I: Wiskott Aldrich syndrome protein (WASp) is a binding partner for c-Src family protein-tyrosine kinases. Curr Biol 1996, 6:981-988.
40. Cory GO, MacCarthy-Morrogh L, Banin S, Gout I, Brickell PM, Levinsky RJ, Kinnon C, Lovering RC: Evidence that the Wiskott-Aldrich syndrome protein may be Involved in lymphoid cell signaling pathways. J Immunol 1996, 157:3791-3795.
41. Symons M, Derry JMJ, Karlak B, Jiang S, Lamahieu V, McCormick F, Francke U, Abo A: Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42HS, is implicated in actin polymerization. Cell 1996, 84:723-734.
42. Kolluri R, Tolias KF, Carpenter CL, Rosen FS, Kirchhausen T: Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42. Proc Natl Acad Sci U S A 1996, 93:5615-5618.
43. Aspenstrom P, Lindberg U, Hall A: Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome. Curr Biol 1995, 6:70-75.
44. Burbelo PD, Drechsel D, Hall A: A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases. J Biol Chem 1995, 270:29071-29074.
45. Miki H, Miura K, Takenawa T: N-WASP, a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kineses. EMBO J 1996, 15:5326-5335. This report, and the one by Li (J Cell Biol 1997, 136:649-658), gives important clues about the function of WASP by describing the function of a protein that is homologous to WASP.
46. Miki H, Miura K, Takenawa T: N-WASP, a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kineses. EMBO J 1996, 15:5326-5335. This report, and the one by Li (J Cell Biol 1997, 136:649-658), gives important clues about the function of WASP by describing the function of a protein that is homologous to WASP.
47. Li R: Bee1, a yeast protein with homology to Wiscott-Aldrich syndrome protein, is critical for the assembly of cortical actin cytoskeleton. J Cell Biol 1997, 136:649-658. This report, and the one by Miki et al. (EMBO J 1996, 15:5326-5335), gives important clues about the function of WASP by describing the function of a protein that is homologous to WASP.
48. Li R: Bee1, a yeast protein with homology to Wiscott-Aldrich syndrome protein, is critical for the assembly of cortical actin cytoskeleton. J Cell Biol 1997, 136:649-658. This report, and the one by Miki et al. (EMBO J 1996, 15:5326-5335), gives important clues about the function of WASP by describing the function of a protein that is homologous to WASP.
49. Remold-O'Donnell E, Cooley J, Shcherbina A, Hagemann TL, Kwan SP, Kenney DM, Rosen FS: Variable expression of WASP in B cell lines of Wiskott-Aldrich syndrome patients. J Immunol 1997, 158:4021-4025.
50. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, Levin M: A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996, 335:1941-1949. This report, and the one by Jouanguy et al. (N Engl J Med 1996, 335:1956-1961), describes the first recognized cases of interferon gamma-receptor deficiency. These reports also help to define a specific, nonredundant, function for interferon gamma and its receptor.
51. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, Levin M: A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996, 335:1941-1949. This report, and the one by Jouanguy et al. (N Engl J Med 1996, 335:1956-1961), describes the first recognized cases of interferon gamma-receptor deficiency. These reports also help to define a specific, nonredundant, function for interferon gamma and its receptor.
52. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile J, Newport M, Levin M, Blanche S, Fischer A, Casanova J: Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996, 335:1956-1961. This report, and the one by Newport et al. (N Engl J Med 1996, 335:1941-1949), describes the first recognized cases of interferon gamma-receptor deficiency. These reports also help to define a specific, nonredundant, function for interferon gamma and its receptor.
53. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile J, Newport M, Levin M, Blanche S, Fischer A, Casanova J: Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996, 335:1956-1961. This report, and the one by Newport et al. (N Engl J Med 1996, 335:1941-1949), describes the first recognized cases of interferon gamma-receptor deficiency. These reports also help to define a specific, nonredundant, function for interferon gamma and its receptor.
54. Abrahamsen TG, Sandersen H, Bustnes A: Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996, 98:1127-1131.
55. Buckley RH, Schiff SE, Schiff Rl, Roberts JL, Marken ML, Peters W, Williams LW, Ward FE: Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency. Semin Hematol 1993, 30:92-101.
56. O'Reilly RJ, Keever C, Keman NA, Brochstein J, Collins N, Flomenberg N, Laver J, Emanuel D, Dupont B, Cunningham I, et al.: HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplant Proc 1987, 19:55-60.
57. Fischer A, Landais P, Friedrich W, Gerritsen B, Fasth A, Porta F, Vellodi A, Benkerrou M, Jais JP, Cavazzana-Calvo M, et al.: Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European group for BMT and the European group for immunodeficiency. Blood 1994, 83:1149-1154.
58. Flake AW, Roncarolo M, Puck JM, Almeida-Porada G, Evans Ml, Johnson MP, Abella EM, Harrison DD, Zanjani ED: Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med 1996, 335:1806-1810. This report, and the one by Wengler et al. (Lancet 1996, 348:1484-1487), describes a new promising technique for bone marrow transplantation for SCID.
59. Flake AW, Roncarolo M, Puck JM, Almeida-Porada G, Evans Ml, Johnson MP, Abella EM, Harrison DD, Zanjani ED: Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med 1996, 335:1806-1810. This report, and the one by Wengler et al. (Lancet 1996, 348:1484-1487), describes a new promising technique for bone marrow transplantation for SCID.
60. Wengler GS, Lanfranchi A, Frusca T, Varardi R, Neva A, Brugnoni D, Gilliani S, Fiorini M, Mella P, Guandalini F, et al.: In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDX1). Lancet 1996, 348:1484-1487. This report, and the one by Flake et al. (N Engl J Med 1998, 335:1806-1810), describes a new promising technique for bone marrow transplantation for SCID.
61. Wengler GS, Lanfranchi A, Frusca T, Varardi R, Neva A, Brugnoni D, Gilliani S, Fiorini M, Mella P, Guandalini F, et al.: In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDX1). Lancet 1996, 348:1484-1487. This report, and the one by Flake et al. (N Engl J Med 1998, 335:1806-1810), describes a new promising technique for bone marrow transplantation for SCID.
62. - SCID: initial trial results after 4 years. Science 1995, 270:475-480.
63. - immunodeficient patients. Science 1995, 270:470-475.
64. Kohn DB, Weinberg KI, Nolta JA, Heisa LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, El-Khoureiy A, et al.: Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995, 1:1017-1023.
65. Candotti F, Johnston JA, Puck JM, Sugamura K, O'Shea JJ, Blaese RM: Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. Blood 1996, 87:3097-3102.
66. Hacein-Bey S, Cavazzana-Calvo M, Le Deist F, Dautry-Varsat A, Hivroz C, Riviere I, Danos O, Heard JM, Sugamura K, Fischer A, De Saint Basile G: γc Gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood 1996, 87:3108-3116.
67. Taylor N, Uribe L, Smith S, Jahn T, Kohn DB, Weinberg K: Correction of interieukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the 1C gene. Blood 1996, 87:3103-3107.
68. Candotti F, Oakes SA, Johnston JA, Notarangelo LD, O'Shea JJ, Blaese RM: In vitro correction of JAK3-deficient severe combined imunodeficiency by retroviral-mediated gene transduction. J Exp Med 1996, 183:2687-2692.
69. Taylor N, Bacon KB, Smith S, Jahn T, Kadlecek TA, Uribe L, Kohn DB, Gelfand EW, Weiss A, Weinberg K: Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene. J Exp Med 1996, 184:2031-2036.